Stock Report

All about this stock under one free report Last Updated: 29-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

GlaxoSmithKline - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$50.39

up-down-arrow $0.12 (0.24%)

As on 28-Aug-2026 13:43EDT

Market cap

info icon

$104,066 Mln

Revenue (TTM)

info icon

$33,203 Mln

P/E Ratio

info icon

16.3

P/B Ratio

info icon

4.4

Div. Yield

info icon

3.5 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 10.22 5.30 4.97 4.22 1.62
EBIT -76.81 -74.12 25.17 -3.50 2.35
Net Profit -80.61 -74.44 53.00 -33.68 -31.62
EPS -74.88 -69.50 42.27 -32.08 1.63
Book Value -- -- 21.31 15.59 -4.14
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 20.0919.9919.8624.7613.12
Net Margin info ----14.52----
Return on equity info 30.1941.7725.8438.0816.78
Return on Capital info 12.9116.40--17.677.29
Return on Assets info 6.868.505.059.493.82
Debt to Equity (x) info ----0.001.081.24

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
--
17.67
7.29
13.77
35.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

25.84

Higher than Peers by 6.87

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
25.84
38.08
16.78
35.69
96.52
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

5.05

Higher than Peers by 2.19

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
5.05
9.49
3.82
7.28
17.88
Peer Median
2.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

19.86

Higher than Peers by 4.04

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
19.86
24.76
13.12
22.39
22.01
Peer Median
15.82
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

14.52

Higher than Peers by 6.29

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
14.52
17.50
8.21
16.25
51.00
Peer Median
8.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

4.97

Lower than Peers by 3.08

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
4.97
0.04
0.03
0.03
0.19
Peer Median
8.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

25.17

Higher than Peers by 16.91

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
25.17
96.45
-39.36
5.19
47.93
Peer Median
8.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

53.00

Higher than Peers by 45.27

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
53.00
121.98
-47.75
-67.05
241.07
Peer Median
7.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

42.27

Higher than Peers by 31.87

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
42.27
1.25
-0.48
-0.67
2.40
Peer Median
10.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-12.45

Lower than Peers by 17.32

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
-12.45
--
--
--
--
Peer Median
4.87
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
--
1.08
1.24
1.35
1.98
Peer Median
0.59
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.24

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
0.24
0.18
0.17
0.21
0.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.82

Lower than Peers by 0.84

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
0.82
0.82
0.78
0.88
0.91
Peer Median
1.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.52

Lower than Peers by 0.68

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
0.52
0.54
0.52
0.62
0.68
Peer Median
1.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

9.56

Higher than Peers by 4.79

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
9.56
11.77
6.26
8.76
7.54
Peer Median
4.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

24.17

Higher than Peers by 2.90

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
24.17
23.71
19.12
31.12
21.20
Peer Median
21.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.35

Lower than Peers by 0.05

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
0.35
0.54
0.47
0.45
0.35
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
--
76.84
89.85
94.27
106.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
--
234.59
255.89
259.17
248.09
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
--
381.09
165.52
183.47
191.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
GlaxoSmithKline - ADR
--
-69.66
180.22
169.97
163.25
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...